NEW YORK, June 2, 2026, 11:11 EDT
Regencell Bioscience Holdings Ltd shares dropped during Tuesday morning, as a new investor alert focused attention on a securities class action deadline set for later this month. The company, listed on Nasdaq, has seen volatile trading in its shares.
The Hong Kong-listed bioscience name saw its shares last change hands at $23.51, off 66 cents, or 2.7%. RGC kicked off the day at $24.10 and moved between $23.50 and $24.38. Volume was about 33,600 shares, according to the most recent data.
Lead plaintiff deadline coming up for Regencell class action. The Gross Law Firm told investors Tuesday they have until June 23 to try for lead plaintiff if they bought Regencell shares between Oct. 28, 2024 and Oct. 31, 2025. The suit claims Regencell was open to market manipulation and says volatility in its stock put investors at risk.
The Rosen Law Firm said in a notice that the lead plaintiff would act for other class members. The firm also said the class is not yet certified, so investors are not automatically represented by counsel.
Regencell disclosed the lawsuit in a filing earlier this month. According to a May 8 Form 6-K, one shareholder filed a putative class action in U.S. District Court for the District of Maryland on April 24. The company said the case is still in its early stages. Regencell said it thinks the claims have no merit and that it will fight them.
Regencell is a small, early traditional Chinese medicine developer working on treatments for attention deficit hyperactivity disorder and autism spectrum disorder. The company focuses on TCM, which uses Chinese medical traditions like herbal formulas. In its most recent annual report, Regencell said it had no products to sell, no revenue from products, had not filed for regulatory approvals, and didn’t have any patents granted or pending.
Regencell’s balance sheet has played a big part in the trade lately. The company posted a net loss of $5.3 million for the six months ended Dec. 31, 2025, widening from last year’s $1.9 million net loss. Cash at year-end was about $2.4 million. Higher general and administrative costs, including legal and professional fees on investigation issues, drove up expenses, according to the filing.
Regencell raised money after that. The company said on May 22 it closed a registered direct offering, selling 985,222 ordinary shares at $20.30 a pop. Gross proceeds came in at around $20 million, according to Regencell, with $19 million from a new fundamental institutional investor. Univest Securities was the sole placement agent.
Biotech stocks slipped, weighing on RGC. The SPDR S&P Biotech ETF dropped roughly 3.3%. Names like Neurocrine Biosciences, Supernus Pharmaceuticals, and Axsome Therapeutics all ended lower. Neurocrine and Supernus each lost about 2.2%. Axsome closed off by about 3.2%.
The match isn’t exact. Neurocrine, Supernus and Axsome have drugs on the market or more established commercial activities in neurology or psychiatry, but Regencell is still in the development phase. Supernus says its products target ADHD, epilepsy, Parkinson’s and migraine. Axsome is working on treatments for central nervous system disorders, including depression, migraine and Alzheimer’s agitation.
The stock traded in a regular U.S. session. Nasdaq’s 2026 holiday schedule has June 19 as the next market holiday, not June 2. Regular trading on most major U.S. exchanges runs from 9:30 a.m. to 4 p.m. Eastern.
But the risk goes both ways. Good legal news, funding updates or new research could help sentiment in this thinly traded stock. But if the class action gets worse, legal bills rise, or the Justice Department trading probe revealed in Regencell’s annual report takes a bad turn, the shares could fall again. Regencell said the DOJ asked for documents and communications and it’s cooperating, but it can’t predict what will happen.
